• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由替代标志物解释的治疗效果比例(PTE)。

Proportion of treatment effect (PTE) explained by a surrogate marker.

作者信息

Chen Cong, Wang Hongwei, Snapinn Steven M

机构信息

Merck Research Laboratories, BL X-27, PO Box 4, West Point, PA 19486, USA.

出版信息

Stat Med. 2003 Nov 30;22(22):3449-59. doi: 10.1002/sim.1575.

DOI:10.1002/sim.1575
PMID:14601012
Abstract

In time-varying covariate analysis of clinical survival data, it is often of interest to estimate the proportion of treatment effect (PTE), along with its confidence intervals, explained by a surrogate marker. The conventional procedure for such an analysis fits data into two working models separately to estimate the treatment effects before and after adjustment of the covariate. The construction of confidence intervals for the PTE under the conventional procedure lacks support by standard statistical software such as SAS, and could be very computationally demanding even after the support is available in the future. To overcome this problem, we propose a new procedure to simplify the computation. Under the new procedure, the treatment effects before and after adjustment of the covariate are simultaneously estimated from a single model. More important than saving computational effort, the new procedure can also be effectively applied to multiple-covariate models for the decomposition of overall treatment effect and for the comparison of PTE among several surrogate markers. The new procedure is applied to the motivating data example from the LIFE study, and demonstrates flexibility that the conventional procedure currently lacks.

摘要

在临床生存数据的时变协变量分析中,通常有兴趣估计由替代标志物解释的治疗效果比例(PTE)及其置信区间。此类分析的传统程序是将数据分别拟合到两个工作模型中,以估计协变量调整前后的治疗效果。在传统程序下,PTE置信区间的构建缺乏诸如SAS等标准统计软件的支持,即使未来有了支持,计算量也可能非常大。为克服这一问题,我们提出了一种新程序以简化计算。在新程序下,协变量调整前后的治疗效果从单个模型中同时估计。比节省计算量更重要的是,新程序还可有效应用于多协变量模型,用于总体治疗效果的分解以及几个替代标志物之间PTE的比较。新程序应用于来自LIFE研究的激励性数据示例,并展示了传统程序目前所缺乏的灵活性。

相似文献

1
Proportion of treatment effect (PTE) explained by a surrogate marker.由替代标志物解释的治疗效果比例(PTE)。
Stat Med. 2003 Nov 30;22(22):3449-59. doi: 10.1002/sim.1575.
2
Quantifying the indirect treatment effect via surrogate markers.通过替代标志物量化间接治疗效果。
Stat Med. 2006 Jan 30;25(2):223-31. doi: 10.1002/sim.2176.
3
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.在氯沙坦干预降低高血压终点事件(LIFE)研究中,氯沙坦对中风有益的潜在机制。
Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435.
4
Quantifying the treatment effect explained by markers in the presence of measurement error.在存在测量误差的情况下,对由标志物解释的治疗效果进行量化。
Stat Med. 2007 Apr 30;26(9):1955-63. doi: 10.1002/sim.2695.
5
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.高血压患者心房颤动发生率与心率随时间变化的关系:LIFE研究
Circ Arrhythm Electrophysiol. 2008 Dec;1(5):337-43. doi: 10.1161/CIRCEP.108.795351. Epub 2008 Dec 2.
6
Counterfactual links to the proportion of treatment effect explained by a surrogate marker.与替代标志物所解释的治疗效果比例的反事实联系。
Biometrics. 2005 Dec;61(4):1102-11. doi: 10.1111/j.1541-0420.2005.00380.x.
7
Alternative methods to evaluate trial level surrogacy.评估试验水平替代指标的替代方法。
Clin Trials. 2008;5(3):194-208. doi: 10.1177/1740774508091677.
8
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.高血压左心室肥厚患者氯沙坦干预降低终点事件(LIFE)研究中的血压降低及降压药物使用情况
Curr Med Res Opin. 2007 Feb;23(2):259-70. doi: 10.1185/030079906X162854.
9
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.与阿替洛尔相比,氯沙坦对2型糖尿病合并高血压患者内皮功能和氧化应激的影响。
J Hypertens. 2007 Apr;25(4):785-91. doi: 10.1097/HJH.0b013e3280287a72.
10
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).抗高血压治疗期间心电图应变模式变化的预后价值:氯沙坦干预降低高血压终点事件研究(LIFE)
Circulation. 2009 Apr 14;119(14):1883-91. doi: 10.1161/CIRCULATIONAHA.108.812313. Epub 2009 Mar 30.

引用本文的文献

1
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.接受帕博利珠单抗联合化疗作为非小细胞肺癌一线治疗的参与者中,肿瘤反应和反应持续时间对生存的影响
Oncol Ther. 2025 Jun 11. doi: 10.1007/s40487-025-00350-6.
2
Measuring Surrogacy in Clinical Research: With an application to studying surrogate markers for HIV Treatment-as-Prevention.临床研究中的代孕测量:应用于研究艾滋病治疗即预防的替代指标
Stat Biosci. 2020 Dec;12(3):295-323. doi: 10.1007/s12561-019-09244-4. Epub 2019 Jun 4.
3
When is the difference method conservative for assessing mediation?
在评估中介效应时,差异法何时具有保守性?
Am J Epidemiol. 2015 Jul 15;182(2):105-8. doi: 10.1093/aje/kwv059. Epub 2015 May 5.
4
Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes.估计不同代谢途径的生物标志物对 2 型糖尿病风险的贡献。
Eur J Epidemiol. 2011 Jan;26(1):29-38. doi: 10.1007/s10654-010-9539-0. Epub 2010 Dec 28.
5
Odds ratios for mediation analysis for a dichotomous outcome.二分类结局中介分析的优势比。
Am J Epidemiol. 2010 Dec 15;172(12):1339-48. doi: 10.1093/aje/kwq332. Epub 2010 Oct 29.